相关临床试验
10
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
10.0%
已完成
4
40.0%
尚未招募
1
10.0%
招募中
1
10.0%
终止
2
20.0%
撤回
1
10.0%
暂无批准数据
- RenovoRx achieved over $400,000 in second quarter 2025 revenue from commercial sales of its FDA-cleared RenovoCath drug-delivery device, marking strong growth in its first two full quarters of commercialization. - The independent Data Monitoring Committee recommended continuation of the pivotal Phase III TIGeR-PaC trial for locally advanced pancreatic cancer after reviewing interim data, with 95 patients randomized and 61 events recorded as of August 2025. - The company expanded its commercial footprint to thirteen cancer center customers approved to purchase RenovoCath, including several National Cancer Institute-designated centers, with four centers actively using the device and making repeat orders.
- The FDA approved SIR-Spheres Y-90 resin microspheres for treating unresectable hepatocellular carcinoma, making it the first and only radioembolization therapy in the U.S. approved for both HCC and metastatic colorectal cancer. - The approval was supported by the DOORwaY90 study, which demonstrated a 98.5% overall response rate and 100% local tumor control rate in 65 patients across 18 U.S. centers. - The therapy uses personalized dosimetry to deliver targeted radiation directly to liver tumors, providing clinicians with expanded treatment flexibility for patients with unresectable HCC. - The median duration of response exceeded 300 days, highlighting the therapy's effectiveness as a liver-directed treatment with a favorable safety profile.
